Yondelis receives EU nod for ovarian cancer
28 September 2009
Francesca Bruce
Please Login to read the full article.
28 September 2009
Francesca Bruce
The EU's
CHMP has given Pharmamar/Johnson and Johnson's chemotherapy drug Yondelis (trabectedin) the green light for treating relapsed platinum-sensitive ovarian cancer. The decision comes soon after the US
FDA delayed approving the drug for the same indication until overall survival...
Please Login to read the full article.
RELATED CONTENT
NEWS
- NICE says final no to Yondelis for ovarian cancer despite patient access scheme
- Lack of "appropriate" evidence prompts NICE no for PharmaMar despite patient access plan
- US filing for Avastin in first-line ovarian cancer 'unlikely' despite European nod
- Francly speaking, Roche launches may not bring the sparkle back for 2012
COMMENT
Other Informa Comment
EVENTS
28 February 2012
Pestana Chelsea Bridge Hotel London
04 March 2012
The Marriott World Center, Orlando, Florida
26 March 2012
Copenhagen, Denmark
JOB OF THE WEEK
Promote your vacancy here
